Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FGFR4 CAR-T cells |
| Synonyms | |
| Therapy Description |
FGFR4 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting FGFR4, which potentially induce cytotoxicity against FGFR4-expressing tumor cells and inhibit tumor growth (PMID: 37774704, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FGFR4 CAR-T cells | FGFR4 CAR T-cells | FGFR4 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting FGFR4, which potentially induce cytotoxicity against FGFR4-expressing tumor cells and inhibit tumor growth (PMID: 37774704, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06865664 | Phase I | FGFR4 CAR-T cells Cyclophosphamide + Fludarabine | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | Recruiting | USA | 0 |